Pricing Log in Create free account
Saturday 17 October 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

299.77 6.47 −2.11%
Market cap
$14.6B
P/E
0.0×
Fwd P/E
29.6×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Charles River Laboratories International, Inc. (CRL) Business Profile

Updated before January 2025

Company Overview

Charles River Laboratories International, Inc. (CRL) is a leading global provider of preclinical and clinical laboratory services for the pharmaceutical, biotechnology, and medical device industries. Founded in 1947 by Dr. Henry Foster in Wilmington, Massachusetts, the company initially focused on breeding laboratory animals for research purposes. Over the decades, CRL has expanded its scope and capabilities through strategic acquisitions and organic growth, becoming a comprehensive partner for drug discovery, development, and safety testing.

Today, CRL operates in over 20 countries, employing more than 20,000 professionals worldwide. The company is headquartered in Wilmington, Massachusetts, and is led by James C. Foster, who has served as Chairman, President, and Chief Executive Officer since 1992. Under his leadership, CRL has grown into a trusted partner for pharmaceutical and biotechnology companies, academic institutions, and government agencies.

Core Business Segments

Charles River Laboratories operates through three primary business segments:

1. Research Models and Services (RMS)

This segment focuses on providing high-quality research models and associated services to support early-stage research and development. Key offerings include:

  • Research Models: CRL is a global leader in the production and supply of laboratory animals, including mice, rats, and other species used in biomedical research.
  • Genetically Engineered Models and Services (GEMS): Custom breeding and genetic engineering services to create models tailored to specific research needs.
  • Research Animal Diagnostic Services: Health monitoring and diagnostic testing for laboratory animals.
  • Insourcing Solutions: On-site management of research animal facilities for clients.

2. Discovery and Safety Assessment (DSA)

This segment provides essential services to accelerate drug discovery and ensure the safety of new therapeutics. Key offerings include:

  • Drug Discovery Services: High-throughput screening, target identification, and lead optimization.
  • Safety Assessment Services: Preclinical testing to evaluate the safety and efficacy of drug candidates, including toxicology, pharmacokinetics, and bioanalysis.
  • Specialized Services: Support for cell and gene therapy development, including viral vector testing and characterization.

3. Manufacturing Support (MS)

This segment focuses on ensuring the quality and safety of biopharmaceutical products. Key offerings include:

  • Microbial Solutions: Endotoxin and microbial detection products and services.
  • Biologics Testing Solutions: Analytical testing and characterization of biologics, including monoclonal antibodies and vaccines.
  • Avian Vaccine Services: Production of specific-pathogen-free (SPF) eggs and related services for vaccine manufacturing.

Business Model

Charles River Laboratories operates a highly integrated business model that combines products, services, and expertise to support the entire drug development lifecycle. The company generates revenue through:

  • Service Contracts: Long-term agreements with pharmaceutical and biotechnology companies for preclinical and clinical testing services.
  • Product Sales: Sales of research models, reagents, and testing kits.
  • Custom Solutions: Tailored services and solutions to meet the unique needs of clients.

CRL’s business model emphasizes collaboration, innovation, and operational efficiency. By offering end-to-end solutions, the company helps clients reduce development timelines and costs while ensuring regulatory compliance.

Strategic Direction

Charles River Laboratories is focused on several strategic priorities to drive future growth:

  • Expansion of Service Offerings: Investing in new capabilities, such as cell and gene therapy development, to address emerging trends in the biopharmaceutical industry.
  • Geographic Growth: Expanding its presence in high-growth markets, including Asia-Pacific and Latin America.
  • Sustainability Goals: Committing to environmental, social, and governance (ESG) initiatives, including reducing greenhouse gas emissions and promoting diversity and inclusion.
  • Digital Transformation: Leveraging advanced technologies, such as artificial intelligence and machine learning, to enhance operational efficiency and data analytics.
  • Strategic Acquisitions: Continuing to acquire complementary businesses to strengthen its portfolio and expand its global footprint.

Competitive Landscape

Charles River Laboratories operates in a highly competitive market, facing competition from both specialized service providers and large contract research organizations (CROs). Key competitors include:

  • Labcorp Drug Development (formerly Covance): A leading CRO offering a wide range of preclinical and clinical services.
  • ICON plc: Specializes in clinical development and commercialization services.
  • WuXi AppTec: A China-based CRO with a strong presence in drug discovery and development.
  • Envigo: Focuses on research models and associated services.
  • Eurofins Scientific: Provides analytical testing services for the pharmaceutical and biotechnology industries.

CRL differentiates itself through its comprehensive service offerings, global reach, and deep expertise in preclinical research.

Risk Factors

Charles River Laboratories faces several risks that could impact its business:

  • Market Dependence: Reliance on the pharmaceutical and biotechnology industries, which are subject to economic and regulatory pressures.
  • Supply Chain Disruptions: Potential delays or shortages in the supply of research models and other critical materials.
  • Regulatory Compliance: Stringent regulations governing preclinical and clinical research, which could lead to increased costs or operational challenges.
  • Competition: Intense competition from other CROs and service providers.
  • Global Events: Geopolitical tensions, pandemics, and other global events that could disrupt operations or demand.

Recent Developments

Charles River Laboratories has made several notable advancements in recent years:

  • Acquisitions: Acquired Cognate BioServices and Vigene Biosciences to enhance its cell and gene therapy capabilities.
  • Partnerships: Collaborated with leading pharmaceutical companies to accelerate vaccine and therapeutic development during the COVID-19 pandemic.
  • Technological Innovations: Invested in digital platforms and automation to improve efficiency and data quality.
  • Sustainability Initiatives: Launched programs to reduce energy consumption and waste across its global operations.

Investment Considerations

Strengths:

  • Comprehensive service offerings that cover the entire drug development lifecycle.
  • Strong reputation and long-standing relationships with leading pharmaceutical and biotechnology companies.
  • Global presence with facilities in key markets.
  • Commitment to innovation and sustainability.

Risks:

  • Dependence on a limited number of large clients for a significant portion of revenue.
  • Exposure to regulatory and economic uncertainties.
  • Competition from other CROs and service providers.

Conclusion

Charles River Laboratories International, Inc. is a trusted partner for the pharmaceutical and biotechnology industries, offering a comprehensive suite of products and services to support drug discovery and development. With a strong market position, a commitment to innovation, and a focus on sustainability, CRL is well-positioned for future growth. However, investors should carefully consider the risks associated with market dependence, regulatory compliance, and competition before making investment decisions.